14.10.20: Not intended for U.S. and UK Media

Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adult patients with relapsed follicular lymphoma (FL) based on the Phase II CHRONOS-1 studymehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news